कृपया अन्य खोज का प्रयास करें
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Christian Jacques | 68 | 2018 | Member of Clinical Advisory Board |
Jennifer Jackson | 71 | 2018 | Independent Director |
Brian M. Stuglik | 65 | 2018 | Independent Director |
Per Anders Göte Samuelsson | 63 | 2012 | Independent Director |
Axel Gaston Glasmacher | 64 | - | Member of Clinical Advisory Board |
Jarl Ulf Jungnelius | 73 | 2011 | Independent Director |
Paul G. Richardson | - | - | Member of Clinical Advisory Board |
Per Wold-Olsen | 77 | 2018 | Independent Chairman of the Board |
Lori Anne Kunkel | 66 | - | Member of Clinical Advisory Board |
Cecilia Daun Wennborg | 61 | 2017 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है